TY  - JOUR
AU  - Laguno, M.
AU  - Von-Wichmann, M. A.
AU  - Van-den-Eynde, E.
AU  - Navarro, J.
AU  - Cifuentes, C.
AU  - Murillas, J.
AU  - Veloso, S.
AU  - Martinez-Rebollar, M.
AU  - Guardiola, J. M.
AU  - Jou, A.
AU  - Gomez-Sirvent, J. L.
AU  - Cervantes, M.
AU  - Pineda, J. A.
AU  - Lopez-Calvo, S.
AU  - Carrero, A.
AU  - Montes, M. L.
AU  - Deig, E.
AU  - Tapiz, A.
AU  - Ruiz-Mesa, J. D.
AU  - Cruceta, A.
AU  - de-lazzari, E.
AU  - Mallolas, J.
PY  - 2016
DO  - 10.1016/j.ijid.2016.10.028
SN  - 1201-9712
UR  - http://hdl.handle.net/10668/18798
T2  - International journal of infectious diseases
AB  - Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-alpha 2a/ribavirin (PEG-IFN/RBV) in the retreatment...
LA  - en
PB  - Elsevier
KW  - PEG-IFN/RBV plus BOC therapy
KW  - HIV-HCV experienced patients
KW  - HCV genotype 1
KW  - Re-treatment
KW  - Área de Gestión Sanitaria Sur de Sevilla
KW  - Triple-therapy
KW  - Coinfected patients
KW  - Phase-2 trial
KW  - Telaprevir
KW  - Ribavirin
KW  - Interferon-alpha-2b
KW  - Safety
TI  - Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study
TY  - research article
VL  - 53
ER  -